Clinical Trials Logo

Clinical Trial Summary

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials.


Clinical Trial Description

GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft issue infections including isolates resistant to existing classes of antimicrobials. This study will be the first administration of GSK2140944 as an intravenous (IV) formulation in humans and will be conducted in two (2) parts. Single IV doses will be explored in Part A and repeat IV doses will be explored in Part B. In addition, this study will evaluate the absolute bioavailability of an oral capsule formulation as compared to the IV formulation in Part A. Both study parts will investigate the safety, tolerability and pharmacokinetic profile of GSK2140944 in healthy adult subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01615796
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date June 4, 2012
Completion date February 21, 2014

See also
  Status Clinical Trial Phase
Completed NCT02202187 - A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT02257398 - Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT01706315 - This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects Phase 1
Completed NCT02000765 - A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects Phase 1
Completed NCT04600752 - Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India Phase 4
Terminated NCT01292213 - A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom N/A
Completed NCT01772238 - Bioequivalence Study of an Amoxicillin-Clavulanic Phase 1
Completed NCT02169583 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Phase 1
Completed NCT01353768 - Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study N/A
Completed NCT01767532 - Bioequivalence Study of Cephalexin Suspension 125 Phase 1
Completed NCT01767571 - Bioequivalence Study of Cephalexin Suspension 250 Phase 1
Completed NCT01510938 - Probiotics in Respiratory Tract Infections in Children Phase 2
Completed NCT00354965 - Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients Phase 1
Completed NCT02688361 - A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution Phase 1
Withdrawn NCT02678234 - An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu Phase 3
Withdrawn NCT02730364 - An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu Phase 3
Completed NCT01767584 - Bioequivalence Study of Cephalexin Tablets 1g Phase 1